tucatinib
-
August 15, 2020
Key Studies in Metastatic Breast Cancer From ASCO 2020 Bookmark
George Lundberg, MDArticle from Medscape curated by Editor in Chief George Lundberg, MD, who notes:
This year’s virtual meeting of the American Society of Clinical Oncology (ASCO) featured five important studies on metastatic breast cancer, as outlined in this video.
Go to full article and video published by Medscape.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
April 22, 2020
FDA Approves Tucatinib in Combination With Trastuzumab/Capecitabine for Advanced Unresectable or Metastatic HER2-Positive Breast Cancer Bookmark
George Lundberg, MDArticle from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes:
Based upon clinical trial results compared to controls, the U.S. Food and Drug Administration (FDA) has approved additional uses for the drug tucatinib (brand name Tukysa) in combination with trastuzumab and capecitabine.
Go to full article published by The ASCO Post.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
April 8, 2020
Tucatinib and Trastuzumab Deruxtecan Show Promise in HER2+ Breast Cancer
Smruti Vidwans, PhDIn 1998, the U.S. Food and Drug Administration (FDA) approved the drug trastuzumab (brand name Herceptin) for people with HER2-positive metastatic breast cancer. Overnight, HER2+ metastatic breast cancer became treatable (though not curable). Subsequent successful clinical studies led to use of trastuzumab earlier in the breast cancer journey—after surgery—to help prevent recurrence, as well as in earlier-stage HER2+ breast cancer. Meanwhile, the FDA approved… Read more »